Micro Labs launches new lipid lowering drug

EPP News Bureau - Bangalore

Micro Labs is all set to launch a breakthrough drug for tighter control of cholesterol, for the first time in India. The drug will be introduced shortly under the brand name “Ezevas” through its specialty division, Cardicare. This drug is a combination of a widely acclaimed statin, Atorvastatin and a novel intestinal cholesterol reuptake inhibitor, Ezetimibe.

The survey on patients with lipid lowering drugs revealed that only 38-50% of the patients achieve recommended lipid treatment goals (NCEP LDL-C). Hence the need for a therapy to complement the existing one has prompted the launch ‘Ezevas.’ The combination works by complementing each other mechanism of action thus improving the success rate in high-risk patients with coronary heart disease, said G N Suresha, vice-president, Cardiology Divisions.

Micro labs is targeting Rs 200 crores lipid lowering segment, which is presently growing at 30% and aims to considerably enhance its market share through this new addition into its product range.

“Launch of Ezeves will further strengthen the armamentarium of the clinician (doctor) for better results and will also help in consolidating our market share in the lipid lowering segment,” explained Dilip Surana, Managing Director, Micro Labs Ltd.